FDA Determines Regulatory Review Period for VOXZOGO Patent Extension Application

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for VOXZOGO, a human drug product, and published a notice as required by law. The FDA made this determination due to a patent extension application submitted to the US Patent and Trademark Office (USPTO), Department of Commerce.